Q2 2024 EPS Estimates for Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Cut by Analyst

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) - Equities research analysts at Zacks Research lowered their Q2 2024 earnings estimates for shares of Zimmer Biomet in a research report issued to clients and investors on Thursday, May 23rd. Zacks Research analyst U. Biswas now anticipates that the medical equipment provider will post earnings of $1.95 per share for the quarter, down from their prior forecast of $2.00. The consensus estimate for Zimmer Biomet's current full-year earnings is $8.10 per share. Zacks Research also issued estimates for Zimmer Biomet's Q1 2025 earnings at $2.06 EPS, Q2 2025 earnings at $2.15 EPS and FY2025 earnings at $8.66 EPS.

ZBH has been the topic of several other reports. Canaccord Genuity Group reissued a "hold" rating and set a $130.00 price target on shares of Zimmer Biomet in a report on Friday, February 23rd. JPMorgan Chase & Co. increased their target price on Zimmer Biomet from $115.00 to $125.00 and gave the company a "neutral" rating in a report on Friday, February 9th. Oppenheimer raised their target price on Zimmer Biomet from $150.00 to $155.00 and gave the stock an "outperform" rating in a research report on Friday, May 3rd. Argus raised shares of Zimmer Biomet from a "hold" rating to a "buy" rating and set a $150.00 price target for the company in a research report on Tuesday, May 21st. Finally, Citigroup raised their price objective on shares of Zimmer Biomet from $134.00 to $140.00 and gave the stock a "neutral" rating in a report on Wednesday, April 3rd. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $134.40.

Zimmer Biomet Stock Performance

ZBH traded up $0.56 during midday trading on Monday, hitting $116.41. 1,084,200 shares of the company traded hands, compared to its average volume of 1,422,651. The company has a quick ratio of 0.80, a current ratio of 1.66 and a debt-to-equity ratio of 0.38. Zimmer Biomet has a 52 week low of $102.00 and a 52 week high of $147.50. The firm has a market capitalization of $23.95 billion, a PE ratio of 25.20, a price-to-earnings-growth ratio of 2.10 and a beta of 1.03. The company's 50-day moving average is $123.26 and its 200 day moving average is $121.82.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share for the quarter, topping the consensus estimate of $1.87 by $0.07. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. The firm had revenue of $1.89 billion during the quarter, compared to analysts' expectations of $1.87 billion. During the same quarter in the previous year, the business earned $1.89 earnings per share. The company's revenue was up 3.2% on a year-over-year basis.

Institutional Investors Weigh In On Zimmer Biomet

Institutional investors have recently bought and sold shares of the business. Schechter Investment Advisors LLC boosted its stake in Zimmer Biomet by 21.6% in the 3rd quarter. Schechter Investment Advisors LLC now owns 4,241 shares of the medical equipment provider's stock worth $476,000 after purchasing an additional 752 shares during the period. Atria Wealth Solutions Inc. boosted its position in shares of Zimmer Biomet by 5.9% during the third quarter. Atria Wealth Solutions Inc. now owns 20,566 shares of the medical equipment provider's stock worth $2,312,000 after acquiring an additional 1,144 shares during the last quarter. International Assets Investment Management LLC grew its stake in Zimmer Biomet by 11,244.9% during the fourth quarter. International Assets Investment Management LLC now owns 66,935 shares of the medical equipment provider's stock valued at $8,146,000 after acquiring an additional 66,345 shares in the last quarter. Amalgamated Bank lifted its stake in Zimmer Biomet by 3.0% in the 3rd quarter. Amalgamated Bank now owns 56,166 shares of the medical equipment provider's stock worth $6,303,000 after purchasing an additional 1,631 shares in the last quarter. Finally, Sequoia Financial Advisors LLC boosted its holdings in shares of Zimmer Biomet by 37.5% during the 4th quarter. Sequoia Financial Advisors LLC now owns 155,965 shares of the medical equipment provider's stock valued at $18,981,000 after purchasing an additional 42,539 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company's stock.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Investors of record on Wednesday, June 26th will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.82%. The ex-dividend date is Wednesday, June 26th. Zimmer Biomet's dividend payout ratio (DPR) is 20.78%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.